Abstract
The potential benefits of transplantation were already recognized in 1968, as reflected in the statement from the Bethesda conference chaired by Francis Moore: “Cardiac transplantation, still in an early stage of development, shows promise for the future treatment of many people with severe heart disease”.1 At that time there were 20 survivors of 50 heart transplant procedures. Since then, cardiac transplantation has evolved from an experimental to an accepted clinical procedure, endorsed by Medicare in 1986 as ‘best therapy’ for end-stage heart failure. The current survival rate is 80–85% at 1 year, 70% at 5 years and 40% at 10 years.2 There have now been over 40,000 transplants performed in the world, involving over 250 heart transplant centres.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Moore FD. Fifth Bethesda Conference Report: Cardiac and other organ transplantation. Am J Cardiol 1968;22:896.
Hosenpud JD, Bennet CE, Keek BRN, Fiel B, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: Fourteenth official report, 1997. J Heart Lung Transplant 1997;13:691.
Bach DS, Bolling SF. Early improvement in congestive heart failure after correction of secondary mitral regurgitation in end-stage cardiomyopathy. Am Heart J 1995;129:1165.
Louie HW, Laks H, Milgalter E, et al. Ischemic cardiomyopathy: criteria for coronary revascularization and cardiac transplantation. Circulation 1991 (Suppl.III):290.
Elefteriades JA, Tolis G, Levi E, Mills LK, Zaret BL. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. J Am Coll Cardiol 1993;22:1411.
Conn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Eingl J Med 1991;325:303.
The SOLVD Investigators: effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685.
Fonarow GC, Chelimsky-Fallick C, Stevenson LW, et al. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol 1992;19:842.
Miller LW, Kubo SH, Young JB, et al. report of the consensus conference on candidate selection for cardiac transplantation. J Heart Lung Transplant 1995;14:562.
Votapka TV, Pennington DG. Circulatory assist devices in congestive heart failure. Cardiol Clin 1994;12:143.
Frazier OH, Rose EA, Macmanus Q, et al. Multicenter clinical evaluation of the HeartMate 1000IP left ventricular assist device. Ann Thorac Surg 1992;53:1080.
Steimle AE, Stevenson LW, Fonarow GC, Hamilton MA, Moriguchi JD. Prediction of improvement in recent onset cardiomyopathy after referral for heart transplantation. J Am Coll Cardiol 1994;23:553.
Semigran MJ, Thaik CM, Filer MA, et al. Exercise capacity and systolic and diastolic ventricular function after recovery from acute dilated cardiomyopathy. J Am Coll Cardiol 1994;24:462
O’Connell JB, Constanzo-Nordin MR, Bubramanian R, et al. Peripartum cardiomyopathy: clinical, hemodynamic, histologic, and prognostic characteristics. J Am Coll Cardiol 1986;8:52.
Regan TJ. Alcohol and the cardiovascular system: a review. J Am Med Assoc 1991;264:377.
Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986;54:563.
Grogan M, Smith HC, Gersh BJ, Wood DW. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992;69:1570.
Middlekauff HR, Weiner I, Stevenson WG, Saxon LA, Stevenson LW. Low dose amiodarone for atrial fibrillation in advanced heart failure restores sinus rhythm and improves functional capacity. Circulation 1992;86:1–808.
Alexander JK. The cardiomyopathy of obesity. Prog Cardiovasc Dis 1985;27:325.
Stevenson LW. Tailored therapy before transplantation for treatment of advanced heart failure: effective use of vasodilators and diuretics. J Heart Lung Transplant. 1991;10:468.
Stevenson LW, Perloff JK. The limited reliability of physical signs for the estimation of hemodynamics in chronic heart failure. J Am Med Assoc 1989;261:884.
Stevenson LW, Tillisch JH. Maintenance of cardiac output with normal filling pressures in dilated heart failure. Circulation 1986;74:1303.
Stevenson LW, Brunken RC, Belil D, et al. Afterload reduction with vasodilators and diuretics decreases mitral valve regurgitation during upright exercise in advanced heart failure. J Am Coll Cardio 1990;15:174.
Mudge GH, Goldstein S, Addonizio LJ, et al. Task force 3: recipient guidelines prioritization. J Am Coll Cardiol 1993;22:21.
Steimle AE, Stevenson LW, Chelimsky-Fallick C, Fonarow GA, Tillisch JH. Prolonged maintenance of cardiac output with normal filling pressures during chronic therapy for advanced heart failure. Circulation 1993;88:I–59A.
Steimle AE, Stevenson LW, Chelimsky-Fallick C, et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation 1997;96:1165.
Fonarow GC, Stevenson LW, Walden JA, et al. Impact of a comprehensive management program on the hospitalization rate for patients with advanced heart failure. J Am Coll Cardiol 1997;30:725.
Waagstein F, Caidahl K, Wallentin I, Bergh C-H, Hjalmarson A. Long-term beta-blockade in congestive cardiomyopathy: effects of short and long-term metoprolol treatment followed by withdrawal and readmission of metoprolol. Circulation 1989;80:551.
Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1442.
Erlebacher JA, Bhardway M, Suresh A, Leber GB, Goldweit RS. Beta-blocker treatment of idiopathic and ischemic dilated cardiomyopathy in patients with ejection fractions < 20%. Am J Coll Cardiol 1993;71:1467.
Hamer AWF, Arkles LB, Johns JA. Beneficial effects of low dose amiodarone in patients with congestive heart failure: a placebo-controlled trial. J Am Coll Cardiol 1989;14:1768.
Doval HC, Nul DR, Grancello et al. Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493.
Singh SN, Fletcher RD, Fisehr SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77.
Wilson JR, Schwartz JS, St. John Sutton M et al. Prognosis in severe heart failure: relating to hemodynamic measurements and ventricular ectopic activity. J Am Coll Cardiol 1983;2:403.
DiSalvo TG, Mathier M, Semigran MJ, Dec GW. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol 1995;25:1143.
Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting enzyme inhibition in patients with severe chronic heart failure. Circulation 1986;73:257.
Conn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819.
Steimle AE, Stevenson LW, Hamilton MA, Fonarow GA. Prediction of spontaneous improvement in recent onset cardiomyopathy after referral for transplantation. Circulation 1993;88:I–93A.
Stevenson LW, Fonarow G, Hamilton M, Tillisch JH. Why cardiac output is not a good hemodynamic target for therapy in advanced heart failure. Circulation 1994;90:I–611.
Stevenson WG, Stevenson LW, Middlekauff HR, Saxon LA. Sudden death prevention in patient with advanced left ventricular dysfunction. Circulation 1993;88:2953.
O’Connell JB, Gunnar RM, Evans RW, Fricker FJ, et al. Task force 1: organization of heart transplantation in the U.S. J Am Coll Cardiol 1993;22:8.
Keogh AM, Freund J, Baron DW, Hickie JB. Timing of transplantation in idiopathic dilated cardiomyopathy. Am J Cardiol 1988;61:418.
Stevenson LW, Couper G, Natterson BJ, et al. Target heart failure population for new therapies. Circulation 1995 (In press).
Lee TH, Hamilton MA, Stevenson LW, et al. Impact of left ventricular cavity size on survival in advanced heart failure. Am J Cardiol 1993;72:672.
Cohn J, Johnson G, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993;87(Suppl.VI):V15.
Szlachic J, Massie B, Kramer B, Topic N, Tubau J. Correlates and prognostic implication of exercise capacity in chronic congestive heart failure. Am J Cardiol 1985;55:1037.
Likoff M, Chandler S, Kay H. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. Am J Cardiol 1987;59:634.
Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991;83:778.
Haywood GA, Rickenbacher PR, Trindade PT, et al. Deaths in patients awaiting heart transplantation: the need to identify high risk category to patients. Circulation 1994;90:I–360.
Stevenson LW, Steimle AE, Chelimsky-Fallick C, et al. Outcomes predicted by peak oxygen consumption during evaluation of 333 patients with advanced heart failure. Circulation 1993;88:I–94A.
Stevenson LW, Steimle AE, Fonarow G, et al. Improvement in exercise capacity of candidates awaiting heart transplantation. J Am Coll Cardiol 1995;25:163.
Stevenson LW, Sietsema K, Tillisch JH, et al. Exercise capacity for survivors of cardiac transplantation or sustained medical therapy for stable heart failure. Circulation 1990;81:78.
Walden JA, Stevenson LW, Dracup K, et al. Extended comparison of quality of life between stable heart failure patient and heart transplant recipients. J Heart Lung Transplant 1994;13:1109.
Stevenson LW, Miller L. Cardiac transplantation as therapy for heart failure. Curr Prob Cardiol 1991;16:219.
Olivari MT, Antolick A, Kaye MP, Jamieson SW, Ring WS. Heart transplantation in elderly patients. J Heart Transplant 1988;7:258.
Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Eight year results of cyclosporin-treated patient with cardiac transplants. J Thorac Cardiovasc Surg 1990;99:500.
Kave MP. The Registry of the International Society for Heart and Lung Transplantation: Tenth Official report—1993. J Heart Lung Transplant 1993;12:541.
Hosenpud JD, DeMarco T, Frazier H, et al. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Circulation 1991;84:III–338.
Stolf NAG, Higushi L, Bocchi E, et al. Heart transplantation in patients with Chagas disease cardiomyopathy. J Heart Transplant 1987;5:307.
Copeland JG, Emery RW, Levinson MM, et al. Selection of patients for cardiac transplantation. Circulation 1987;75:2.
Olbrisch ME, Levenson JL. Psychological evaluation of heart transplantation candidates: an international survey of process, criteria and outcomes. J Heart Lung Transplant 1991;10:948.
Rodriguez MD, Colon A, Santiago-Dolphin EA. Psychosocial profile of noncompliant patients. Transplant Proc 1991;23:1807.
Herrick CM, Mealey PC, Tischner LL, Holland DS. Combined heart failure-transplant program: advantages in assessing medical compliance. J Heart Transplant 1987;6:141.
Penn I. Cancers after cyclosporin therapy. Transplant Proc 1988;20:276.
Erickson KW, Costanzo-Nordin MR, O’Sullivan EJ, et al. Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation. J Heart Transplant 1990;9:526.
Costard-Jackie A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 1992;19:48.
Kaye MP. The Registry of the International Society for Heart and Lung Transplantation: Ninth official report. J Heart Lung Transplant 1992;599:11.
Desruennes M, Muneretto C, Grandjbakhch I, et al. Heterotopic heart transplantation: current status in 1988. J Heart Transplant 1989;8:475.
Wright RS, Levine MS, Bellamy EP, et al. Ventilatory and diffusion abnormalities in potential heart-transplant recipients. Chest 1990;98:816.
Radovancevic B, Poindexter S, Birovljev S, et al. Risk factors for development of accelerated coronary artery disease in cardiac transplant recipients. Eur J Cardiothorac Surg 1990;4:309.
Myers BD, Peterson C, Molina C, et al. Role of cardiac atria in the human renal response to changing plasma volume. Am J Physiol 1988;254:F562.
Wei CM, Kao PC, Lin JT, Heublein DM, Schaff HV, Burnett JC Jr. Circulating b-atrial natriuretic factor in congestive heart failure. Circulation 1993;88:1016.
Bourge RC, Naftal DC, Costanzo M, et al. Risk factors for death after cardiac transplantation: a multi-institutional study. J Heart Lung Transplant 1993;12:549.
Laffel GL, Barnett AI, Finkelstein S, et al. The relation between experience and outcome in heart transplantation. N Engl J Med 1992;327:1220.
Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992;20:527.
Natterson PD, Steveason WG, Saxon LA, Middlekauff HR, Stevenson LW. Risk of arterial embolization in 224 patients awaiting cardiac transplantation. Am Heart J 1995;129:564.
Konstram MA, Dracup K, Baker DW, et al. Heart failure: evaluation and care of patient with left-ventricular systolic dysfunction. Rockville, MD: US Dept. of Health and Human Services. 1994.
Chelimsky-Fallick C, Middlekauff HR, Stevenson WG, et al. Amiodarone therapy does not compromise subsequent heart transplantation. J Am Coll Cardiol 1992;20:1556.
Stevenson LW, Warner SL, Steimle AE, et al. The impending crisis awaiting cardiac transplantation: modelling a solution based on selection. Circulation 1994;89:450.
Stevenson LW, Bourge RC, Naftel DC, et al. Deterioration and death on the current waiting list: a multicenter study of patients awaiting heart transplantation. Circulation 1995;92:I–124.
Norman JC, Colley DA, Igo SR, et al. Prognostic indices for survival during postcardiotomy intra-aortic balloon pumping. J Thorac Cardiovasc Surg 1977;74:709.
Loisance DY, Deleuze PH, Houel R, et al. Pharmacologic bridge to cardiac transplantation: current limitations. Ann Thorac Surg 1993;55:310.
McCarthy PM, Sabik JF. Implantable circulatory support devices as a bridge to heart transplantation. Sem Thorac Cardiovasc Surg 1994;6:174.
Rose EA, Stevenson LW (Eds). Management of End-Stage Heart Disease, Lippincott-Raven, Philadelphia, 1998.
Evans RW. Executive Summary: The National Cooperative Transplantation Study. Report BHARC-100-91-020. Seattle: Battelle Seattle Research Center, June 1991.
Pfeffer MA, Braunwald E, Moye LA, et al. (on behalf of the SAVE investigators). Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669.
The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293.
CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative New Scandinavian Enalapril Survival Study. N Engl J Med 1987;316:1429.
Stevenson LW. Role of exercise in the evaluation of candidates for cardiac transplantation: In: Wasserman K, editor. Exercise gas exchange in heart disease. New York: Futura;1996;27
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Kluwer Academic Publishers
About this chapter
Cite this chapter
Stevenson, L.W. (1999). Selection and Management of the Potential Candidate for Cardiac Transplantation. In: Masters, R.G. (eds) Surgical Options for the Treatment of Heart Failure. Developments in Cardiovascular Medicine, vol 225. Springer, Dordrecht. https://doi.org/10.1007/978-0-585-29191-8_5
Download citation
DOI: https://doi.org/10.1007/978-0-585-29191-8_5
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-6130-5
Online ISBN: 978-0-585-29191-8
eBook Packages: Springer Book Archive